Comments to FDA: Developing Nicotine Replacement Therapy Drug Products

Share page:

Comments | Apr 12, 2019

Docket Number:
FDA-2019-D-0297

CHPA welcomes the opportunity to comment on the draft guidance on indications for nicotine replacement therapies (NRT).

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement: OTC Pain Relievers and COVID-19 Vaccines